Abeona Therapeutics Estimates That Its Current Cash And Cash Equivalents, Restricted Cash And Short-term Investments Of $62.7M, Credit Facility, And Proceeds Of $75M From Underwritten Offering In May Is Expected To Provide Cash Runway Into 2026
Abeona Therapeutics Estimates That Its Current Cash And Cash Equivalents, Restricted Cash And Short-term Investments Of $62.7M, Credit Facility, And Proceeds Of $75M From Underwritten Offering In May Is Expected To Provide Cash Runway Into 2026
Abeona Therapeutics估计，其目前的现金和现金等价物、6,270万美元的限制性现金和短期投资、信贷额度以及5月份承销发行的7500万美元收益预计将为2026年提供现金流
Abeona Therapeutics Estimates That Its Current Cash And Cash Equivalents, Restricted Cash And Short-term Investments Of $62.7M, Credit Facility, And Proceeds Of $75M From Underwritten Offering In May Is Expected To Provide Cash Runway Into 2026
Abeona Therapeutics估计，其目前的现金和现金等价物、6,270万美元的限制性现金和短期投资、信贷额度以及5月份承销发行的7500万美元收益预计将为2026年提供现金流
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。